NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Omaveloxolone for treating Friedreich's ataxia in people 16 years and over [ID6423]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Biogen (omaveloxolone) Patient/carer groups • Ataxia UK • Beacon • Brain and Spine Foundation • Brain Charity • Cardiomyopathy UK • Diabetes UK • Gene People • Genetic Alliance UK • Neurological Alliance • Scoliosis Support & Research • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association of British Neurologists • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Society for Blood and Marrow Transplantation • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • Institute of Neurology • National Neurosciences Advisory Group • Primary Care and Community Neurology Society • Royal College of General Practitioners • Royal College of Nursing	General • All Wales Inherited Metabolic Disease Service • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee • Oxford Ataxia Centre • Paediatric Ataxia Centre, National Hospitals for Neurology and Neurosurgery • Sheffield Children's Centre • The London Ataxia Centre, National Hospitals for Neurology and Neurosurgery • The Sheffield Ataxia Centre, Department of Neurology, Royal Hallamshire Hospital Comparator companies

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
• Royal College of Occupational Therapists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <u>Others</u> • Department of Health and Social Care • NHS England • NHS Genomic Network of Excellence • NHS Genomic Medicine Service	None <u>Relevant research groups</u> • Brain Research UK • Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research • Oxford-Harrington Rare Disease Centre • UCL Queen Square Institute of Neurology <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.